Leadership and Governance
Board of Directors
Our leadership team bring many years of expertise in life sciences, finance and venture, as well as the dynamism and strategic awareness to apply it.
Chief Executive Officer
Lead Independent Non-Executive Director
Dr Jean-Michel Cosséry
Independent Non-Executive Director
Dr Kirsten Drejer
Independent Non-Executive Director
Rudy joined the Board of Malin as Lead Independent Non-Executive Director in July 2018.
Rudy held the role of CEO of Polyganics B.V., a Dutch medical technology company, from 2013 until its successful sale in October 2022. He currently serves as Chairman on the Boards of NeutriLeads, Medichem S.A, VitalNext and the Supervisory Board of Organ Assist. He has formerly served as CEO of Synthon, President of Cardinal Health, President and executive board member of Royal Numico and held the position of worldwide VP/General Manager of the Business Development Biosciences Division of Becton Dickinson.
Luke joined the Board of Malin as Non-Executive Director in March 2020.
Luke is head of the Credit and Special Situations group at Pentwater Capital Management LP, an organisation which holds a 26% economic interest in Malin through a number of counterparties. Prior to joining Pentwater, Luke held a senior investment position with a large private principal trading and investment firm and began his career with Goldman Sachs & Company. In his roles, Luke has served on the boards of several private and public companies across a range of sectors. He has a B.S. in Finance from Miami of Ohio University and is an alumnus of Harvard Business School.
Jean-Michel joined the Board of Malin as Independent Non-Executive Director in July 2018.
Jean-Michel previously spent 10 years at GE Healthcare as the Chief Marketing Officer and VP, Global Marketing. More recently, he served as VP, North American Oncology with Eli Lilly, as well as Managing Director Northern Europe. He serves on the boards of Exact Tx, a medtech company listed in Norway; SOPHiA GENETICS SA, a health care technology company based in Switzerland and EraCal Therapeutics Ltd, a biotech company based in Switzerland. He served as a non-executive director on the board of Diurnal Group plc until the successful sale of that company in October 2022. Jean-Michel served on the board of Immunocore Limited in the UK until its IPO and on the board of Kymab Group Limited until its sale to Sanofi in 2021.
Jean-Michel holds an MBA from the Rotterdam School of Management (Erasmus University). He received his PhD with honours in Nuclear Chemistry and Neurobiology from the University of Paris and conducted post-doctoral research in Neuropharmacology at the National Institutes of Health in the US. Additionally, he holds a Pharm D with honours in Pharmacology from the University of Paris.
Liam joined the Board of Malin as Independent Non-Executive Director in March 2015 and was appointed Chair in August 2019.
Liam is also a non-executive director of Horizon Therapeutics plc and was president of the Institute of Directors in Ireland from 2013 to 2015. He served with Elan Corporation plc from 1993 until 2014 in various roles including executive vice president and as an executive director.
A graduate of University College Dublin, Liam is also a Fellow of Chartered Accountants Ireland and a Chartered Director.
Darragh was appointed Chief Executive Officer in September 2019, having previously held the positions of Chief Business and Financial Officer, and Chief Financial Officer of Malin. Darragh joined Malin in March 2015.
Prior to joining Malin, Darragh held a number of senior finance positions in Elan Corporation plc and worked with PwC in Dublin, the US and Canada.
Darragh is a Fellow of Chartered Accountants Ireland.
Kirsten joined the Board of Malin as Independent Non-Executive Director in March 2020.
Kirsten founded and served as CEO of Symphogen, a Danish private biopharmaceutical company, and has extensive board experience on both private and public companies across the life sciences sector, including Zealand Pharma, where she currently serves as vice-chairman of the board, Bioporto and Alligator Bioscience. She was previously a member of the boards of The Danish National Advanced Technology Foundation and The Danish Growth Fund. A graduate of the Danish University of Pharmaceutical Sciences, Kirsten has an MSc in Pharmacy and a PhD in Pharmacology.
Chris joined the Board of Malin as Non-Executive Director in April 2022.
Chris is the head of the Equity Capital Markets Group at Pentwater Capital Management LP, an organisation which holds a 28.3% economic interest in Malin. Prior to joining Pentwater, Chris held a Portfolio Manager position at Magnetar Financial UK LLP and began his career as a senior trader with Carlson Capital UK LLP. Chris has over 20 years of investment experience at alternative/private investment funds. He has a B.A. in Economics from Dartmouth College in the US.
Andrea was appointed as Head of Finance in May 2022. Before joining Malin, Andrea worked with Sebela Pharmaceuticals and Doosan Bobcat in a number of senior finance positions, having previously worked with PwC’s international and domestic business assurance group in Dublin.
A graduate of National College of Ireland, Andrea is also a Fellow of Chartered Accountants Ireland.
Fiona has served as Company Secretary of Malin since September 2018, prior to which she was Head of Tax from 2015. Before joining Malin, Fiona worked at Elan Corporation plc and with Deloitte’s international tax group in Dublin and New York.
Fiona is an associate of the Irish Taxation Institute and of Chartered Accountants Ireland.